Infantile Neuroaxonal Dystrophy (INAD) Pathway

Infantile Neuroaxonal Dystrophy (INAD) Pathway

Overview

Infantile neuroaxonal dystrophy (INAD), also known as PLA2G6-associated neurodegeneration (PLAN), is a rare autosomal recessive neurodegenerative disorder characterized by progressive axonal dystrophy, iron accumulation in the brain, and developmental regression[@gregory2009]. The disease is caused by mutations in the PLA2G6 gene, which encodes calcium-independent phospholipase A2 (iPLA2-VI), a critical enzyme involved in membrane lipid metabolism, axonal maintenance, and mitochondrial function[@bose2009].

The clinical presentation typically begins in the first two years of life with rapid deterioration of motor and cognitive functions. Children develop hypotonia, spasticity, ataxia, and visual impairment. The disease follows a relentlessly progressive course, with most patients becoming wheelchair-bound by age 5-10 and dying in the teenage years or early twenties[@ibrahim2022]. Less commonly, PLA2G6 mutations can cause adult-onset dystonia-parkinsonism, highlighting the phenotypic variability of this genetic disorder.

Genetics and Molecular Basis

PLA2G6 Gene

The PLA2G6 gene (OMIM: 603604) is located on chromosome 22q13.1 and encodes the group VI calcium-independent phospholipase A2 (iPLA2-VI)[@bose2009]. This enzyme hydrolyzes the sn-2 position of phospholipids, releasing free fatty acids and lysophospholipids. The protein exists in multiple splice variants, with the longest form (iPLA2-VIbeta) being predominantly expressed in the brain and enriched in neurons and astrocytes.

Infantile Neuroaxonal Dystrophy (INAD) Pathway

Overview

Infantile neuroaxonal dystrophy (INAD), also known as PLA2G6-associated neurodegeneration (PLAN), is a rare autosomal recessive neurodegenerative disorder characterized by progressive axonal dystrophy, iron accumulation in the brain, and developmental regression[@gregory2009]. The disease is caused by mutations in the PLA2G6 gene, which encodes calcium-independent phospholipase A2 (iPLA2-VI), a critical enzyme involved in membrane lipid metabolism, axonal maintenance, and mitochondrial function[@bose2009].

The clinical presentation typically begins in the first two years of life with rapid deterioration of motor and cognitive functions. Children develop hypotonia, spasticity, ataxia, and visual impairment. The disease follows a relentlessly progressive course, with most patients becoming wheelchair-bound by age 5-10 and dying in the teenage years or early twenties[@ibrahim2022]. Less commonly, PLA2G6 mutations can cause adult-onset dystonia-parkinsonism, highlighting the phenotypic variability of this genetic disorder.

Genetics and Molecular Basis

PLA2G6 Gene

The PLA2G6 gene (OMIM: 603604) is located on chromosome 22q13.1 and encodes the group VI calcium-independent phospholipase A2 (iPLA2-VI)[@bose2009]. This enzyme hydrolyzes the sn-2 position of phospholipids, releasing free fatty acids and lysophospholipids. The protein exists in multiple splice variants, with the longest form (iPLA2-VIbeta) being predominantly expressed in the brain and enriched in neurons and astrocytes.

Over 100 pathogenic mutations in PLA2G6 have been identified across the coding sequence, including missense, nonsense, splice site, and frameshift mutations[@karakaya2022]. These mutations cluster in the lipase domain and affect catalytic activity, protein stability, or membrane association. Common founder mutations have been reported in specific populations, including a splice site mutation (c.1634A>G) in Middle Eastern families and a missense mutation (p.Arg752Cys) in European populations.

Protein Function

iPLA2-VI plays multiple critical roles in cellular homeostasis:

Lipid Metabolism: The enzyme catalyzes the release of arachidonic acid from membrane phospholipids, providing the substrate for cyclooxygenases and lipoxygenases that produce prostaglandins and leukotrienes involved in inflammation and cell signaling[@bose2009].

Membrane Remodeling: iPLA2-VI participates in phospholipid remodeling cycles that maintain membrane fluidity and composition, which is essential for proper vesicle trafficking and organelle function.

Signal Transduction: Lysophospholipids generated by iPLA2-VI activity act as second messengers that regulate various cellular processes including cell survival, migration, and immune responses.

Pathogenic Mechanisms

Mitochondrial Dysfunction

PLA2G6 mutations lead to profound mitochondrial impairment through multiple mechanisms[@wu2021]. iPLA2-VI is localized to mitochondrial membranes where it regulates phospholipid composition and supports mitochondrial function. Loss of enzyme activity results in:

Axonal Transport Dysfunction

Neurons are highly dependent on axonal transport to maintain synaptic function and deliver essential components between the cell body and distal processes[@morogan2023]. PLA2G6 dysfunction disrupts multiple aspects of axonal transport:

Kinesin and Dynein Dysfunction: Motor proteins require properly organized membrane domains for efficient cargo movement. Altered phospholipid composition of axonal membranes in PLA2G6 mutants impairs the association and function of kinesin and dynein motors.

Vesicle Trafficking Defects: The continuous cycling of synaptic vesicles between nerve terminals and the soma is disrupted, leading to synaptic vesicle depletion and impaired neurotransmitter release.

Organelle Distribution: Mitochondria, endosomes, and lysosomes fail to distribute properly along axons, creating localized deficits in energy supply and degradative capacity.

Axonal Swellings: The accumulation of organelles and transport cargo creates characteristic axonal swellings (spheroids) that are the pathological hallmark of INAD. These swellings contain dilated mitochondria, dense bodies, and membranous whorls.

Iron Accumulation

Brain iron accumulation is a consistent feature of INAD and related parkinsonism syndromes[@peng2022]. The mechanism involves dysregulation of iron metabolism pathways:

Oxidative Stress

PLA2G6 dysfunction creates a state of chronic oxidative stress through multiple pathways[@wu2021]:

• Arachidonic Acid Cascade: While iPLA2-VI generates arachidonic acid for signaling, excessive or dysregulated activity can lead to production of reactive oxygen species (ROS) through lipoxygenase and cyclooxygenase pathways.
• Mitochondrial ROS: Damaged mitochondria produce excess superoxide and hydrogen peroxide. Combined with reduced antioxidant capacity, this leads to progressive oxidative damage to proteins, lipids, and DNA.
• Lipid Peroxidation: The same membrane lipid abnormalities that impair mitochondrial function also make neurons more susceptible to lipid peroxidation chain reactions.
• Antioxidant Defenses: Studies show reduced glutathione levels and impaired Nrf2-mediated antioxidant response in PLA2G6-deficient cells.

Tau Pathology

Accumulating evidence shows that PLA2G6 dysfunction leads to tau hyperphosphorylation and aggregation[@hauser2022]:

Clinical Features

Age of Onset

INAD typically presents between 6 months and 2 years of age[@ibrahim2022]. Early developmental milestones may be normal before the onset of regression, creating a distinctive pattern of initial normal development followed by rapid decline.

Neurological Manifestations

Motor Symptoms:

• Progressive hypotonia evolving to spasticity
• Ataxia and gait instability
• Dystonia and choreoathetosis
• Vision loss due to optic atrophy
• Seizures in approximately 50% of patients

• Developmental regression affecting language and cognition
• Progressive intellectual disability
• Loss of previously acquired skills

• Feeding difficulties and failure to thrive
• Respiratory problems
• Dysphagia

Neuroimaging

MRI findings in INAD include:

Diagnosis

Genetic Testing

Molecular confirmation through PLA2G6 sequencing is the definitive diagnostic method[@karakaya2022]. Whole exome sequencing or targeted gene panels are typically used. Carrier testing for at-risk family members and prenatal diagnosis for affected families are available when the familial mutations are known.

Biomarkers

Research into biomarkers for INAD includes:

• Neurofilament Light Chain (NfL): Elevated in serum and CSF, correlating with disease severity
• Oxidized Phospholipids: Elevated in PLA2G6-deficient cells and can serve as treatment monitoring biomarkers
• Iron Markers: Ferritin levels may be elevated in CSF

Therapeutic Approaches

Current Management

No disease-modifying therapies are available, and treatment is supportive[@faridar2024]:

Experimental Strategies

Multiple therapeutic approaches are under investigation:

Gene Therapy: Adeno-associated virus (AAV) vectors carrying wild-type PLA2G6 are being developed for CNS delivery. Preclinical studies in mouse models have shown partial rescue of neurobehavioral phenotypes.

Small Molecule Activation: Screenings have identified compounds that enhance residual iPLA2-VI activity or bypass the enzymatic defect through parallel pathways.

Iron Chelation: Deferiprone and other iron chelators are being studied for their ability to reduce brain iron accumulation and slow disease progression.

Neuroprotective Strategies: N-acetylcysteine, CoQ10, and other antioxidants are being tested for their ability to reduce oxidative stress and support mitochondrial function.

Cell Replacement: Induced pluripotent stem cell (iPSC)-derived neurons from INAD patients are being developed for autologous cell therapy approaches.

Related Pages

Genes and Proteins

• [PLA2G6 Gene](/genes/pla2g6)
• [Parkin Protein](/proteins/parkin-protein)
• [PINK1 Protein](/proteins/pink1-protein)

Mechanisms

• [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction)
• [Axonal Transport Dysfunction](/mechanisms/axonal-transport-defects)
• [Iron Dysregulation in Neurodegeneration](/mechanisms/iron-dysregulation-neurodegeneration)
• [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)
• [Tau Pathology in Alzheimer's Disease](/mechanisms/tau-pathology)

Diseases

• [Leigh Syndrome](/diseases/leigh-syndrome)
• [Alpers Syndrome](/diseases/alpers-syndrome)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neurodegeneration with Brain Iron Accumulation (NBIA)](/diseases/nbia-disorders)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Infantile Neuroaxonal Dystrophy (INAD) Pathway discovered through SciDEX knowledge graph analysis: